Syndax Pharmaceuticals Reports 93% Revenue Growth to $72.8 Million in Q2 2026

Syndax Pharmaceuticals, Inc. reported significant financial performance improvements in its latest 10-Q filing for the second quarter of 2026. The company generated total revenues of $72.8 million for the three months ended June 30, 2026, a 93% increase from $38.0 million in the same period last year. This growth was driven by a substantial rise in product revenue, which reached $54.7 million, up from $28.6 million in the prior year, and collaboration revenue of $18.1 million, compared to $9.4 million in the previous year. For the first half of 2026, total revenues were $137.7 million, significantly higher than $57.8 million reported for the same period in 2025.

Despite the revenue growth, Syndax reported a net loss of $49.4 million for the second quarter, an improvement from a loss of $71.8 million in the same quarter of 2025. For the six months ended June 30, 2026, the net loss was $92.0 million, down from $156.7 million in the prior year. The company attributed the reduced losses to increased product sales and a decrease in operating expenses, which totaled $112.8 million for the quarter, compared to $107.3 million in the same period last year.

Strategically, Syndax has made notable advancements, including the successful commercialization of its two FDA-approved products, Revuforj and Niktimvo. The company reported approximately 1,500 prescriptions for Revuforj in the second quarter, reflecting a 121% increase year-over-year. Additionally, the company announced the expansion of its pipeline with two new assets, SNDX-4321 and SNDX-62122, aimed at addressing significant unmet needs in cancer treatment. The company continues to collaborate with Incyte on the commercialization of Niktimvo, which has also seen increased sales.

Operationally, Syndax's cash and cash equivalents surged to $336.5 million as of June 30, 2026, compared to $134.9 million at the end of 2025. The company also issued $250 million in convertible senior notes in June 2026, enhancing its liquidity position. The total employee headcount remained stable, with ongoing investments in research and development, which accounted for $68.0 million in the second quarter, reflecting a focus on advancing clinical trials and product development.

Looking ahead, Syndax anticipates continued revenue growth driven by its product portfolio and ongoing clinical trials. The company expects to leverage its cash reserves and financing activities to support its operational and developmental needs. However, it acknowledges the inherent uncertainties in clinical development and the potential for future losses as it continues to invest heavily in research and development.